Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe.
The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema.
The company was incorporated in 1993 and is headquartered in Montreal, Canada.
As of September 25, 2025, Theratechnologies Inc. operates as a subsidiary of CB Biotechnology, LLC.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 8, 25 | -0.09 Decreased by -552.00% | -0.03 Decreased by -234.81% |
| Apr 8, 25 | 0.00 Increased by +102.30% | 0.04 Decreased by -94.65% |
| Feb 19, 25 | -0.23 Decreased by -186.12% | 0.07 Decreased by -427.00% |
| Oct 10, 24 | 0.06 Increased by +300.00% | 0.03 Increased by +100.00% |
| Jul 10, 24 | 0.02 Increased by +118.18% | -0.02 Increased by +200.00% |
| Apr 10, 24 | -0.10 Increased by +77.27% | -0.12 Increased by +16.67% |
| Feb 21, 24 | -0.08 Increased by +11.11% | -0.24 Increased by +66.67% |
| Sep 26, 23 | -0.03 Increased by +62.50% | -0.29 Increased by +89.66% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| May 31, 25 | 17.73 M Decreased by -19.48% | -4.46 M Decreased by -552.08% | Decreased by -25.17% Decreased by -661.42% |
| Feb 28, 25 | 19.05 M Increased by +17.23% | 117.00 K Increased by +102.61% | Increased by +0.61% Increased by +102.23% |
| Nov 30, 24 | 25.00 M Increased by +6.61% | -7.90 M Decreased by -186.86% | Decreased by -31.61% Decreased by -169.08% |
| Aug 31, 24 | 22.60 M Increased by +8.37% | 3.09 M Increased by +514.34% | Increased by +13.68% Increased by +482.35% |
| May 31, 24 | 22.02 M Increased by +25.46% | 987.00 K Increased by +109.86% | Increased by +4.48% Increased by +107.86% |
| Feb 29, 24 | 16.25 M Decreased by -18.39% | -4.48 M Increased by +57.09% | Decreased by -27.58% Increased by +47.42% |
| Nov 30, 23 | 23.45 M Increased by +9.48% | -2.75 M Increased by +65.25% | Decreased by -11.75% Increased by +68.26% |
| Aug 31, 23 | 20.86 M Increased by +0.21% | -746.00 K Increased by +90.12% | Decreased by -3.58% Increased by +90.14% |